---
layout: default
title: Saline
parent: 僅模型預測 (L5)
nav_order: 184
evidence_level: L5
indication_count: 0
---

# Saline
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# SALINE: Drug Repurposing Evaluation — Insufficient Data for Assessment

## One-Sentence Summary

SALINE has no recorded original indications in this evidence pack and no DrugBank identifier has been assigned.
The TxGNN model returned **no predicted new indications** for this entry,
meaning **no clinical trial or literature evidence** could be retrieved to support any repurposing direction.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded |
| Predicted New Indication | None |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — no predictions generated |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Why Assessment is Not Possible

No mechanism of action data is available for SALINE in this evidence pack, and no DrugBank ID has been assigned. Without a valid DrugBank identifier, the TxGNN model is unable to map this entry to the knowledge graph and therefore cannot generate any repurposing predictions.

Saline (sodium chloride solution) is typically used as an intravenous fluid replacement agent, wound irrigation solution, and pharmaceutical excipient or diluent rather than as a pharmacologically active compound in its own right. This is the most likely explanation for the absence of TxGNN predictions — the model is designed to identify new therapeutic applications for active drug molecules, and a non-specific substance such as saline falls outside its intended scope.

There is also a possibility that "SALINE" was entered as a placeholder or test value, or that it represents a misidentified compound. The absence of a DrugBank ID, brand name, original indications, and UK marketing authorisations all point towards an incomplete or erroneous data entry rather than a genuine candidate drug.

---

## Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN predictions were generated for SALINE, and all foundational data elements — DrugBank identifier, mechanism of action, original indications, and UK marketing authorisations — are absent. A drug repurposing evaluation cannot be meaningfully conducted without these inputs.

**To proceed, the following is needed:**
- Confirm whether "SALINE" is the intended drug name or a data entry error
- Assign a valid DrugBank ID to enable knowledge graph mapping
- If SALINE refers to a specific formulation (e.g., hypertonic saline for cystic fibrosis), clarify the active component and resubmit under the correct INN
- Retrieve mechanism of action data from DrugBank once the compound is correctly identified
- Re-run the TxGNN prediction pipeline with a confirmed DrugBank ID
- Obtain MHRA marketing authorisation data if the compound is authorised in the UK under a different name
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

